Drug Profile
Japanese encephalitis vaccine - Shandong Hengye Biotech
Alternative Names: Vero cell-derived inactivated Japanese encephalitis vaccine - Shandong Hengye BiotechLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Shandong Hengye Biotech
- Developer Jiangsu Provincial Center for Disease Control and Prevention; Shandong Hengye Biotech
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Japanese encephalitis
Most Recent Events
- 20 Sep 2017 Phase-III development for Japanese encephalitis (In infants, Prevention) is ongoing in China (Parenteral) (Shandong Hengye Biotech website, September 2017)
- 18 Jul 2017 Shandong Hengye Biotech announces intention to carry out production registration declaration of vaccine for Japanese encephalitis (In infants, Prevention) in China in 2018 (Shandong Hengye Biotech website, September 2017)
- 01 Oct 2014 Phase-III clinical trials in Japanese encephalitis (In infants, Prevention) in China (Parenteral)